FDA Inspection 1181741 — Jubilant HollisterStier General Partnership
The FDA completed an inspection of Jubilant HollisterStier General Partnership on Oct 7, 2022 in Kirkland. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI)
- End Date
- Oct 7, 2022
- Fiscal Year
- 2023
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Kirkland (Canada)
Additional Details
Postmarket Adverse Drug Experience (PADE)